Archive for the ‘BioAtla’ Category

BioAtla LLC

July 1st, 2015 | Posted in 2015, BioAtla

A China-based investor group has purchased $30 million in equity in the San Diego-based BioAlta, a global biotech company. The funds will be used to accelerate the development of the company’s antibody drug pipeline. BioAtla’s Conditionally Active Biologics platform is designed to produce a new class of immunotherapeutics that target selected microenvironments within the body.

BioAtla

February 20th, 2014 | Posted in 2014, BioAtla

BioAtla – San Diego:  Recently announced that it licensed exclusive global rights to develop and commercialize its TH22 pathway-directed antibody compound for the treatment of inflammatory bowel diseases and oncologic indications to BioMotiv, the therapeutics accelerator for The Harrington Project for Discovery and Development.  In conjunction with the agreement, BioMotiv established Kodosil Bio, which will […]